Deutsche Bank Bio-Fest

For investors that dabble in biotech stocks, it is common knowledge that these entities react to drug trial results and FDA approvals more so than on earnings announcements and ratings changes. There is no better better example of this occurring than in the price action of Biogen Idec Inc (...